vs
Side-by-side financial comparison of Civeo Corp (CVEO) and Bio-Techne (TECH). Click either name above to swap in a different company.
Bio-Techne is the larger business by last-quarter revenue ($295.9M vs $161.6M, roughly 1.8× Civeo Corp). Bio-Techne runs the higher net margin — 12.8% vs -4.0%, a 16.8% gap on every dollar of revenue. On growth, Civeo Corp posted the faster year-over-year revenue change (7.1% vs -6.4%). Over the past eight quarters, Bio-Techne's revenue compounded faster (4.2% CAGR vs -1.4%).
The Civeo Corporation is an American accommodation services multinational corporation. It is a spin-off of Oil States International. It is a public company listed on the New York Stock Exchange.
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
CVEO vs TECH — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $161.6M | $295.9M |
| Net Profit | $-6.5M | $38.0M |
| Gross Margin | 22.7% | 64.6% |
| Operating Margin | -0.1% | 18.4% |
| Net Margin | -4.0% | 12.8% |
| Revenue YoY | 7.1% | -6.4% |
| Net Profit YoY | 58.1% | 68.3% |
| EPS (diluted) | $-0.58 | $0.24 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $161.6M | $295.9M | ||
| Q3 25 | $170.5M | — | ||
| Q2 25 | $162.7M | $317.0M | ||
| Q1 25 | $144.0M | $316.2M | ||
| Q4 24 | $151.0M | $297.0M | ||
| Q3 24 | $176.3M | $289.5M | ||
| Q2 24 | $188.7M | $306.1M | ||
| Q1 24 | $166.1M | $303.4M |
| Q4 25 | $-6.5M | $38.0M | ||
| Q3 25 | $-455.0K | — | ||
| Q2 25 | $-3.3M | $-17.7M | ||
| Q1 25 | $-9.8M | $22.6M | ||
| Q4 24 | $-15.4M | $34.9M | ||
| Q3 24 | $-5.1M | $33.6M | ||
| Q2 24 | $8.2M | $40.6M | ||
| Q1 24 | $-5.1M | $49.1M |
| Q4 25 | 22.7% | 64.6% | ||
| Q3 25 | 25.7% | — | ||
| Q2 25 | 25.3% | 62.7% | ||
| Q1 25 | 20.4% | 67.9% | ||
| Q4 24 | 18.6% | 65.3% | ||
| Q3 24 | 21.4% | 63.2% | ||
| Q2 24 | 25.4% | 66.4% | ||
| Q1 24 | 21.5% | 67.4% |
| Q4 25 | -0.1% | 18.4% | ||
| Q3 25 | 4.1% | — | ||
| Q2 25 | 1.7% | -7.5% | ||
| Q1 25 | -3.8% | 12.2% | ||
| Q4 24 | -6.7% | 16.0% | ||
| Q3 24 | 0.0% | 13.8% | ||
| Q2 24 | 6.9% | 15.0% | ||
| Q1 24 | -1.1% | 22.1% |
| Q4 25 | -4.0% | 12.8% | ||
| Q3 25 | -0.3% | — | ||
| Q2 25 | -2.0% | -5.6% | ||
| Q1 25 | -6.8% | 7.1% | ||
| Q4 24 | -10.2% | 11.7% | ||
| Q3 24 | -2.9% | 11.6% | ||
| Q2 24 | 4.4% | 13.3% | ||
| Q1 24 | -3.1% | 16.2% |
| Q4 25 | $-0.58 | $0.24 | ||
| Q3 25 | $-0.04 | — | ||
| Q2 25 | $-0.25 | $-0.11 | ||
| Q1 25 | $-0.72 | $0.14 | ||
| Q4 24 | $-1.04 | $0.22 | ||
| Q3 24 | $-0.36 | $0.21 | ||
| Q2 24 | $0.56 | $0.26 | ||
| Q1 24 | $-0.35 | $0.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $14.4M | $172.9M |
| Total DebtLower is stronger | — | $260.0M |
| Stockholders' EquityBook value | $174.4M | $2.0B |
| Total Assets | $477.4M | $2.5B |
| Debt / EquityLower = less leverage | — | 0.13× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $14.4M | $172.9M | ||
| Q3 25 | $12.0M | — | ||
| Q2 25 | $14.6M | $162.2M | ||
| Q1 25 | $28.4M | $140.7M | ||
| Q4 24 | $5.2M | $177.5M | ||
| Q3 24 | $17.9M | $187.5M | ||
| Q2 24 | $7.4M | $152.9M | ||
| Q1 24 | $16.8M | $145.3M |
| Q4 25 | — | $260.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $346.0M | ||
| Q1 25 | — | $330.0M | ||
| Q4 24 | $43.3M | $300.0M | ||
| Q3 24 | — | $300.0M | ||
| Q2 24 | — | $319.0M | ||
| Q1 24 | — | $389.0M |
| Q4 25 | $174.4M | $2.0B | ||
| Q3 25 | $182.5M | — | ||
| Q2 25 | $209.4M | $1.9B | ||
| Q1 25 | $220.7M | $2.0B | ||
| Q4 24 | $236.4M | $2.1B | ||
| Q3 24 | $282.2M | $2.1B | ||
| Q2 24 | $297.4M | $2.1B | ||
| Q1 24 | $297.4M | $2.0B |
| Q4 25 | $477.4M | $2.5B | ||
| Q3 25 | $491.1M | — | ||
| Q2 25 | $508.8M | $2.6B | ||
| Q1 25 | $423.8M | $2.6B | ||
| Q4 24 | $405.1M | $2.7B | ||
| Q3 24 | $477.6M | $2.7B | ||
| Q2 24 | $483.2M | $2.7B | ||
| Q1 24 | $513.1M | $2.7B |
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | — | 0.16× | ||
| Q4 24 | 0.18× | 0.14× | ||
| Q3 24 | — | 0.14× | ||
| Q2 24 | — | 0.15× | ||
| Q1 24 | — | 0.19× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $19.3M | — |
| Free Cash FlowOCF − Capex | $14.5M | — |
| FCF MarginFCF / Revenue | 8.9% | — |
| Capex IntensityCapex / Revenue | 3.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $2.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $19.3M | — | ||
| Q3 25 | $13.8M | — | ||
| Q2 25 | $-2.3M | $98.2M | ||
| Q1 25 | $-8.4M | $41.1M | ||
| Q4 24 | $9.5M | $84.3M | ||
| Q3 24 | $35.7M | $63.9M | ||
| Q2 24 | $32.4M | $75.5M | ||
| Q1 24 | $6.0M | $81.0M |
| Q4 25 | $14.5M | — | ||
| Q3 25 | $8.2M | — | ||
| Q2 25 | $-6.8M | $93.3M | ||
| Q1 25 | $-13.7M | $31.0M | ||
| Q4 24 | $1.8M | $77.5M | ||
| Q3 24 | $28.2M | $54.7M | ||
| Q2 24 | $27.0M | $57.5M | ||
| Q1 24 | $372.0K | $64.5M |
| Q4 25 | 8.9% | — | ||
| Q3 25 | 4.8% | — | ||
| Q2 25 | -4.2% | 29.4% | ||
| Q1 25 | -9.5% | 9.8% | ||
| Q4 24 | 1.2% | 26.1% | ||
| Q3 24 | 16.0% | 18.9% | ||
| Q2 24 | 14.3% | 18.8% | ||
| Q1 24 | 0.2% | 21.3% |
| Q4 25 | 3.0% | — | ||
| Q3 25 | 3.3% | — | ||
| Q2 25 | 2.8% | 1.5% | ||
| Q1 25 | 3.7% | 3.2% | ||
| Q4 24 | 5.1% | 2.3% | ||
| Q3 24 | 4.2% | 3.2% | ||
| Q2 24 | 2.8% | 5.9% | ||
| Q1 24 | 3.4% | 5.4% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.82× | ||
| Q4 24 | — | 2.42× | ||
| Q3 24 | — | 1.90× | ||
| Q2 24 | 3.93× | 1.86× | ||
| Q1 24 | — | 1.65× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CVEO
Segment breakdown not available.
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
